文献速递主动脉疾病

激光原位开窗在胸主动脉腔内修复术中的应用:单中心分析

Laser in situ Fenestration in Thoracic Endovascular Aortic Repair: A Single-Center Analysis.
PubMed 文献 · Ann Vasc Surg · 2021-06-18

本研究回顾性分析24例接受胸主动脉腔内修复术(TEVAR)联合激光原位开窗(LISF)重建弓上血管的患者,技术成功率100%,主要并发症率21%,包括卒中3例和30天死亡2例,平均随访261天期间32%患者需再干预。LISF联合TEVAR技术可行,在择期和急诊中均具实用性,对于复杂弓部病变且开放手术风险高的患者是潜在选择。

要点

  • LISF联合TEVAR技术成功率100%,可用于择期和急诊弓部病变。
  • 主要并发症率21%,包括卒中3例和30天死亡2例。
  • 平均随访261天,32%患者需要再干预。

核心结论

  • LISF用于TEVAR中分支血管重建技术可行,适用于多种主动脉弓病变,在择期和急诊中均具实用性。
  • 相比开放手术,LISF联合TEVAR的并发症和死亡率表现更有利,对于复杂弓部病变且开放手术风险高的患者是潜在选择。

研究设计与样本

  • 单中心回顾性分析,纳入2017至2020年24例接受TEVAR联合LISF的患者。
  • 患者由心脏外科和血管外科组成的主动脉团队评估,认为不适合开放手术。
  • 术前CT血管造影和术中血管内超声确定支架尺寸,根据病变决定放大率。
  • 使用2.3 mm Spectranetics激光,入路部位由术者决定。
  • 覆盖球囊扩张支架移植物以0-10%放大率释放。

主要发现

  • 24例患者共创建30个开窗(左锁骨下动脉19例,左颈总动脉3例,无名动脉7例,右锁骨下动脉1例),每人1个开窗18例,2个开窗6例。
  • 适应证包括动脉瘤8例、慢性夹层伴动脉瘤样变8例、急性夹层4例、壁内血肿2例、假性动脉瘤2例。
  • 13例为择期,11例为急诊;技术成功率100%。
  • 12例患者接受同期(8例)或分期(4例)解剖外旁路。
  • 主要并发症率21%,包括卒中3例和30天死亡2例;总体并发症率58%。

临床怎么用

  • 对于复杂主动脉弓病变且开放手术风险高的患者,可考虑LISF联合TEVAR作为潜在治疗选择。
  • 需由多学科主动脉团队评估,并告知患者该技术的超说明书使用性质。
  • 术后需密切随访,关注卒中和再干预风险。

局限性

  • 单中心小样本回顾性研究,随访时间有限,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Laser in situ fenestration (LISF) is an expanding technique for arch vessel revascularization in thoracic endovascular aortic repair (TEVAR). We present a single center's early and midterm outcomes using adjunctive LISF with TEVAR for treatment of various arch pathologies. METHODS: 24 patients underwent TEVAR with LISF (2017-2020). Patients were evaluated by an Aortic Team consisting of cardiothoracic and vascular surgeons and were deemed unfit for open surgical repair. Informed consent emphasized the procedure's off-label nature. Thoracic stent-grafts were sized by preoperative Computed Tomography Angiogram and intraoperative Intravascular Ultrasound, with oversizing determined by pathology. Extra-anatomic debranching was performed in staged or concurrent fashion based on urgency of repair and access site options for branch fenestration. A 2.3 mm Spectranetics laser was used, with access site determined at surgeon discretion. Covered balloon expandable stent-grafts were deployed with 0-10% oversizing. RESULTS: In 24 patients, a total of 30 fenestrations were created (LSA N = 19, LCCA N = 3, Innominate N = 7, RSA N = 1) with 1 (N = 18) or 2 (N = 6) fenestrations/patient. Indications included aneurysm (8), chronic dissection with aneurysmal degeneration (8), acute dissection (4), intramural hematoma (2), and pseudoaneurysm (2). 13 cases were elective, and 11 were emergent. Technical success was 100%. 12 patients underwent concurrent (N = 8) or staged (N = 4) extra-anatomic bypass. The major complication rate was 21%, including stroke (N = 3) and 30-day mortality (N = 2). The overall complication rate was 58%. Over a mean follow up of 261 days (15-864 days), 7 patients (32%) have required reinterventions. CONCLUSIONS: LISF for branch revascularization in TEVAR is technically feasible for treating various aortic arch pathologies, demonstrating practicality in both elective and emergent settings. With a morbidity and mortality profile that is favorable compared to that of open repair, LISF with TEVAR is a promising potential option for patients with complex arch pathology and prohibitive open surgical risk.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Evans E, Veeraswamy R, Zeigler S, et al. Laser in situ Fenestration in Thoracic Endovascular Aortic Repair: A Single-Center Analysis. Ann Vasc Surg. 2021. PMID: 34153488. doi:10.1016/j.avsg.2021.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。